Key statistics
On Tuesday, Phaxiam Therapeutics SA (2E40:MUN) closed at 1.82, 10.06% above the 52 week low of 1.65 set on Oct 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.82 |
---|---|
High | 1.82 |
Low | 1.82 |
Bid | -- |
Offer | -- |
Previous close | 1.82 |
Average volume | 300.00 |
---|---|
Shares outstanding | 10.01m |
Free float | 9.95m |
P/E (TTM) | -- |
Market cap | 18.39m EUR |
EPS (TTM) | -3.46 EUR |
Data delayed at least 15 minutes, as of Nov 12 2024 07:05 GMT.
More ▼
Announcements
- Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024
- PHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’étude de phase II GLORIA aux Etats-Unis
- PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
- Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 8 octobre 2024
- PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study
- PHAXIAM Therapeutics annonce la validation d’une nouvelle étude de phase 2, PHAGOSCARPA, sponsorisée par un investigateur
- PHAXIAM fait le point sur ses activités et publie ses résultats financiers du premier semestre 2024
- PHAXIAM Provides Business and Financial Update For the First Half of 2024
More ▼